Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence

Published:2022-12-22 Issue:4 Volume:25 Page:1112-1116
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Bril Fernando¹²³^ORCID,Kalavalapalli Srilaxmi²,Lomonaco Romina²,Cusi Kenneth²

Affiliation:

1. Division of Endocrinology, Diabetes and Metabolism University of Alabama at Birmingham Birmingham Alabama USA

2. Division of Endocrinology, Diabetes and Metabolism University of Florida Gainesville Florida USA

3. Division of Endocrinology, Diabetes and Metabolism VA Medical Center Birmingham Alabama USA

Funder

Burroughs Wellcome Fund

American Diabetes Association

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14936

Reference21 articles.

1. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

2. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

3. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis

4. Current therapies and new developments in NASH

5. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis;RSC Medicinal Chemistry;2024

2. Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials;Frontiers in Endocrinology;2023-03-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3